Post on 15-Mar-2019
GUNA-TF are Transfer Factors protein-based innovative homeopathic
medicines at D7 (7 X for US Physicians) potency (10-7).
The Transfer Factors are therapeutically active at a dosage of 100
ng/day; to obtain this specific concentration (corresponding to the
amount of Transfer Factors that are contained in a Guna-TF capsule),
the technique of homeopathic preparation has been used in order to
realize a standard production according to current Good
Manufacturing Practice.
Transfer factors are short ribonucleopeptide chains with antigenic
messenger RNA bases connected with short peptide chains
composed of 6 or more amino acids. In simple words, they are tiny
molecules providing for immune defence. They are all natural
substances that work by “teaching” our own immune system to
identify infectious agents that attack our body every day.
Guna-TF are manufactured through a patented procedure by
extracting them from lymph cells activated by specific antigens
(viruses, yeasts, etc.).
These Lymphoid lines are being cultivated in vitro and dialysed: in
this way, the so-called DLE (Dialyzable Leukocyte Extract) can be
containing over 200 molecules, weighting between 1.000 and
20.000 Dalton. Among these, there are Transfer Factors proteins
responsible for the transfer of cell-mediated immunity.
GGUUNNAA--TTFF??WHAT ARE GUNA-TF?
GUNA-TF
One of the most common theories on the mechanism of action of
Transfer Factors is that they are part of the receptor lying on the Th
lymphocyte surface in a steric position that is necessary to identify
the specific antigenic agent.
Administering Transfer Factors proteins means activating the
mechanisms of receptor re-synthesization (specific receptors of a
specific antigen) by Th lymphocytes, thus enhancing their receptor
capacity and hence their immune effectiveness.
Transfer Factors are also capable of activating intracell
mechanisms responsible for the production of cytokines, which are
important intracell communication messengers between different
immune response intermediates. In particular, they activate the
synthesis of pro-inflammatory interleukins (for instance IL1, IL6,
TNF, INF, etc) which are essential to induce an effective
physiological response towards a pathogen agent.
GUNA-TF
GGUUNNAA--TTFF GUNA-TF MECHANISM OF ACTION
GUNA-TF
The chronicization and recurrence of an infectious disease represent
the most evident sign that the Immune System has been attacked by
pathogen agents.
Transfer Factors struggle against the body non-response by providing it
with the necessary factors to help the Immune System face the antigen
attack.
Guna-TF treatment is capable of transferring the immune pathway of
the donor of Transfer Factors to the patient to be treated to trigger an
autologous response that has to be sufficient and suitable to fight the
antigenic attack in a physiological way.
The treatment with Guna-TF is suitable in the forms of cell-mediated
immune selected deficit.
The response is specific only toward the antigen codifying the Transfer
Factor:
• Herpes simplex type 1 and 2 ·Guna-TF Herpes• Monilia albicans ·Guna-TF Candida• HPV ·Guna-TF Papilloma
GGUUNNAA--TTFF FOR WHICH DISEASES CANGUNA-TF BE USED?
á100 ng/die = quantity of Transfer Factors proteins that are therapeutically active and correspond to the quantity of TF D7 (7 X for US Physicians) in a capsule of Guna-TF
áTransfactor = Transfer of cell-mediated immunity
áTransfactor = Antigen-specific immunotherapy
á
á Transfactor = Physiological treatment of chronic recurrent infections diseases
á Transfactor = Effective and risk-free treatment
HOW TO USE GUNA-TF:
• Guna-TF are in capsules for oral use.
• Standard dosage: 1 capsule/day for 5 continuous days (for
instance: from Monday to Friday, excluding Saturday and Sunday)
for 3-4 months without break.
PACKAGE SIZE
Bottle of 20 x 230 mg capsules.
GGUUNNAA--TTFFGUNA-TF
Tran
sfac
tor:
Key
note
s
GGUUNNAA--TTFF HHEERRPPEESSGUNA-TF HERPES
GUNA-TF HERPES
Composition Transfer Factors-HSV
type 1 and 2 at D7 potency
(7X for US Physicians).
Indications Herpes labialis and Herpes genitalis
recurrent infections; herpetic
keratoconjunctivitis; herpetic-like
cutaneous infections.
Dosage 1 capsule/day for 5 continuous days (for instance:
from Monday to Friday, excluding Saturday and Sunday)
for 3-4 months without break.
Package size Bottle of 20 x 230 mg capsules.
Combination with other Guna medicines:
· Strengthening of immune defenses in Herpes simplex I and II infections:
Guna-TF Herpes + Guna-Virus
A clinical research study has been carried out on 44 patients, 22 affected by labial herpes and 22affected by genital herpes.All the patients have been treated for 6 continuous months with a Transfer Factor preparationobtained from in vitro culture extract of specific HSV 1 and 2 from dyalized bovine lymphocytes.
In the monitoring period before the treatment (the 44 patients have been monitored globally 26.660days long) there have been 544 reacutizations with a 61.2 Relapse Index.
The monitoring period during and after treatment has been of 16.945 days for the 44 patients. Inthis period there have been 121 reacutizations with a 21.4 Relapse Index.
From Pizza G, Viza V, De Vinci C, Palareti AP, Cuzzocrea DE, Fornarola V & Baricordi OR. “Orally administered HSV-specific
transfer factor (TF) prevents genital and/or labial herpes relapses”. Biotherapy, Vol. 9:62-72, 1996.
Prevention of recurrent labial and genital herpes infections
Clinical case
Composition Transfer Factor Monilia albicans
at D7 potency
(7X for US Physicians).
Indications Recurrent Candida infections;
mucocutaneous yeast problems
in different body areas; dermatitis.
Dosage 1 capsule/day for 5 continuous days
(for instance from Monday to Friday,
excluding Saturday and Sunday) for 3-4 months without break.
Package size Bottle of 20 x 230 mg capsules.
Combination with other Guna medicines:
· Acute and chronic Vulvo-vaginites as a consequence of yeast problems
(Candidiasis):
Guna-TF Candida + MycoxTM + CitomixTM (20 drops three times/day for 1 month)
· Dysbiotic Candidiasis: Guna-TF Candida + EubioflorTM+ CitomixTM
(20 drops three times/day for 2 months)
GGUUNNAA--TTFF CCAANNDDIIDDAAGUNA-TF CANDIDA
GUNA-TF CANDIDA
Guna-TF-Candida in chronic mucocutaneous Candidiasis
Clinical case
A clinical research study has been carried out on 15 patients (3 M; 12 F) affected by ChronicMucocutaneous Candidiasis (6 patients with oral Candidiasis and 9 patients with VaginalCandidiasis).The patients have been treated with a Transfer Factor preparation from in vitro culture extract ofMonilia albicans. The CMI (Cell-Mediated Immunity) has been considered through the LeukocyteMigration Test (LMT) and the Lymphocyte Stimulation Test (LST) with the presence of Candidiasis lysatebefore, during and after treatment.83.9% of LMTS Test were positive during treatment, showing an increased incidence of Candidiasisantigen reactivity.In the monitoring period improvements of the health condition have been recorded.
From Masi M., De Vinci C., Baricordi O.R. “Transfer Factor in chronic mucocutaneous candidiasis”. Biotherapy. 9(1-3)97-103, 1996.
GGUUNNAA--TTFF PPAAPPIILLLLOOMMAAGUNA-TF PAPILLOMA
GUNA-TF PAPILLOMA
Composition Transfer Factor Papillomavirus
at D7(7 X for US Physicians) potency.
Indications Recurrent Papillomavirus infections;
condylomatoses; post-surgical
condyloma treatment; warts.
Dosage 1 capsule/day for 5 continous days
(for instance from Monday to Friday,
excluding Saturday and Sunday) for 3-4 months without break.
Package size Bottle of 20 x 230 mg capsules.
Combination with other Guna medicines:
· Strengthening of immune defenses in Human Papilloma Virus (HPV)
infections: Guna-TF Papilloma + CitomixTM
A clinical research study has been carried out on 160 patients, both male and female, affected byHPV (Papilomavirus) lesions or PAP test or biopsy positive to koilocytosis to consider the results of atreatment with Transfer Factor preparation from in vitro culture HPV extract to prevent relapses.The protocol provided for the use of one capsule/day for 5 continuous days/week for 8 weeks andthen one capsule/day for 3 days/week (on alternate days) for another 4 weeks.The viral HPV lesions have almost disappeared in the patients treated.In 97% of the cases where the electrosurgical treatment has been used in conjunction with thepreparation no further persistent symptoms of disease have been recorded.
From M. Destro Castaniti. “L'utilizzo del Transfactor 11 nella patologia virale da HPV (casistica di 160 casi)”. La Medicina
Biologica, 2000/4; 95-100.
Use of TF-Papilloma in HPV disease
Clinical case
1. Blume M.R., Rosenbaum E.H., Cohen R.J.,
Gerhow J, Glassberg AB, Shepley E. -
Adjuvant immunotherapy of high risk stage
I melanoma with transfer factor. Cancer,
47, 882-888, 1981.
2. Borden E.C. - Augmented tumour-associa-
ted antigen expression by interferons. JNCI,
80, 148-149, 1988.
3. Bukowski R.M., Deodhar S., Hewlett J.S.,
Greenstreet R. - Randomized controlled trial
of transfer factor in stage II malignant mela-
noma. Cancer 51, 269-272, 1983.
4. Conti F., Orlandini A. - Trattamento di mani-
festazioni allergiche con Transfer Factor
(TF). La Medicina Biologica, 1998/3; pp.
35-39.
5. Corrado F., Pizza G., De Vinci C., Corra-
do G., Mannini D., Maver P., Ferri C., Aiel-
lo E. - L'impiego del transfer factor nel car-
cinoma prostatico metastatizzato. In Atti del
Convegno Internazionale sul Cancro della
Prostata. Garofalo F, Tomaselli V Eds. Mon-
duzzi Editore, Bologna. p. 89-92, 1988.
6. Corrado F., Pizza G., De Vinci C., Corra-
do G. - Il trattamento con transfer factor del-
le metastasi ossee da adenocarcinoma del-
la prostata. In: Le Metastasi, Atti XII Cong
Naz Oncol, Saccani F, Becchi G, Carretti
D, Maltoni C Ed, Monduzzi Editore, Bolo-
gna, 1233-1235, 1986.
7. Corrado F., Pizza G. - Tentativas de inmu-
noterapia en los tumores del aparato urina-
rio. Arch Esp Urol, 37, 659-666, 1984.
8. Destro Castaniti M. - L'utilizzo del Transfac-
tor 11 nella patologia virale da HPV (casi-
stica di 160 casi) - La Medicina Biologica
2000/4, pagg. 95-100.
9. Fudenberg H.H., Fudenberg H.H. - Transfer
Factor: Past, present and future. Annu Rev
Pharmacol Toxicol, 29: 475-516, 1989.
10. Fudenberg H.H., Smith C.L. - Immunomodu-
lation and immunotherapy: an overview of
biologic and synthetic agents and their
effects on the human immune system. EOS
Riv. Immunol Immunopharmacol, 1: 3-11,
1981.
11. Fudenberg H.H., Wilson G.B. et al - Dialy-
zable Leucocyte Extracts (Transfer Factor): A
review of clinical results and immunological
methods for donor selection, evaluation of
activities and patient monitoring. In:
Thymus, Thymic Hormones and T
Lymphocytes. Eds: Aiuti F, Wigzell H. Proc
Serono Symp, Academic Press, London,
38: 391-421, 1980.
12. Fudenberg H.H., Wilson G.B., Tsang K.Y.
- Evaluation of transfer cator potency and
prediction of clinical response. In: Immuno-
modulation: New Frontiers and Advances.
Eds: Fudenberg H.H., Whitten H., Ambro-
gi F. Plenum Press, New York, pp.115-
130, 1984.
13. Fusjisawa T., Yamaguchi Y., Kimura H. et al
- Adjuvant immunotherapy of primary resec-
ted lung cancer with transfer factor. Cancer,
54, 663-669, 1984.
14. Gonzalez R.L., Wong P., Spitler L.E. - Adju-
vant immunotherapy with Transfer Factor in
patients with melanoma metastatic to lung.
Cancer, 45, 57-63, 1980.
15. Greiner J.W., Fisher P.B., Pestka S., Schlom
J.: Differential effects of recombinant human
leukocyte interferon on cell surface antigen
expression. Cancer Res, 46, 4984-4990,
1986.
16. Huo B. - Clinical application of Transfer
Factor in China.ibidem pp. 451-459.
17. Jones J.F., Minnich L.L., Jeter W.-S., Pritchett,
Fulginiti V.A., Wedgwood R.J. - treatment of
childood combined Epstein-Barr virus/cyto-
GUNA-TF
Literature references
megalovirus infection with oral bovine trans-
fer factor. Lancet 2: 122-124, 1981.
18. Jones J.F., Pizza G., De Vinci C. - Infectious
mononucleosis: immunotherapy with EBV-
specific Transfer Factor? J Exp Pathol, 3(4),
399-406, 1987.
19. Kirkpatrick C.H. - Transfer Factor - Perspective
in human and veterinary medicine. J Exp
Pathol, vol 3(4), 383-398, 1987.
20. Lawrence H.S. - Proc. Soc. Exp. Biol Med
71, 516, 1949.
21. Malzac J. - Applicazioni terapeutiche dei
Transfer-factors nella prassi clinica quotidiana:
prime esperienze e risultati clinici - La Medici-
na Biologica 1997/2 Supplemento, pagg.
50-54.
22. Malzac J. - Transfer Factor, specifica attivazio-
ne della memoria del linfocita - La Medicina
Biologica 1996/2 Supplemento, pagg. 46-
50.
23. Mazzella G., Ronchi M., Villanova N.,
Mohamed A.A., Pizza G., De Vinci C., Viza
D., Roda E., Barbara L. - Treatment of chronic
B virus hepatitis with specific Transfer Factor. J
Exp Pathol, 3, 421-423, 1987.
24. Meduri R., Campos E., Scorolli L., De Vinci
C., Pizza G., Vizà D. - Efficacia del Transfer
Factor nel trattamento di pazienti con infezio-
ni erpetiche oculari ricorrenti. In: “Biotherapy”
9/1996.
25. Neequaye J., Viza D., Pizza G., Levine P.H.,
De Vinci C. et al - Specific Transfer Factor
with activity against Epstein-Barr virus reduces
late relapse in endemic Burkitt's lymphoma.
Anticancer Res, 10,: 1183-1188, 1990.
26. Nkrumah F.K., Pizza G., Neequaye J., Viza
D., De Vinci C., Levine P.H. - Transfer Factor
in prevention of Burkitt's Lymphoma relapses.
J Exp Pathol, 3, 463-469, 1987.
27. Orlandini A. - Il Transfer Factor: la proteina
responsabile del trasferimento della reattività
cellulo mediata verso antigeni specifici - La
Medicina Biologica 1996/2; pagg. 37-42.
28. Paddock G.V., Wilson G.B., Lin F.K.,
O'Leary, Fudenberg H.H. - In: Electrophoresis
'81, Eds: Allen R, Arnaud P. Edited by De
Gruyter, NY, pp. 479-486, 1981.
29. Pizza G., Viza D., Ablashi D.V., Faggioni A.,
Armstrong G., Levine P.H., De Vinci C., Inno-
centi R. - Transfer of reactivity with in vitro pro-
duced Transfer Factor in Rhesus and Owl
monkeys. Lymphokine Res, 4, 351-357,
1985.
30. Pross HF, Baines M. - Studies of human natu-
ral killer cells. I. In vivo parameters affecting
normal cytotoxic function. Int J Cancer, 29,
383-390, 1982.
31. Roda E., Pizza G., Viza D., Mastroroberto L.,
De Vinci C., Barbara L.: Transfer Factor for
the treatment of HBsAg positive chronic acti-
ve hepatitis. Proc Soc Biol Med (Usa), 178,
405-410, 1985.
32. Sasakawa S., Takenouchi K., Masumoto C.,
Mura T., Saito S et al: Clinical trials of dialy-
zable leukocyte extract (RCTF-I) in Japan. In:
Leukocyte Dialyzates and Transfer Factor, Eds
Mayer V, Borvak, pp.141-145. Inst Virol, Slo-
vak Acad Sci, 1987.
33. Schwartz R.S., Jeter W.S. - Oral-administra-
tion of human dializable transfer factor in a
patient with psoriasis. Arch Dermatol, 117:
3-4, 1981.
34. Viza D., Rosenfeld F., Phillips J., Vich J.M.,
Denis, Bonissent J.F., Dogbe K. - Specific
bovine transfer factor for the treatment of her-
pes infections. In: Immunobiology of Transfer
Factor, Kirkpatrick CH, Burger DR, Lawrence
HS Eds, Ac Press, NY, 245-259, 1983.
35. Viza D. - Transfer Factor: un immunomodu-
latore nella lotta contro le malattie infettive -
La Medicina Biologica 2000/4, pagg.
31-37.
36. Viza D., Orlandini A. - Il Transfer Factor spe-
cifico (TF 11) nel trattamento delle affezioni
muco-cutanee da Papillomavirus (HPV) - La
Medicina Biologica 1999/3, pagg. 11-
15.
37. Whyte R.I., Schork A., Sloan H., Orringer
M.B., Kirsh M.M. - Adjuvant treatment
using for bronchogenic carcinoma: long-
term follow-up. Ann Thorac Surg 53, 391-
6, 1992.
38. Wilson G.B., Fudenberg H.H. - Is contro-
versy about “transfer factor therapy” near
the end? Immunol Today. 4: 157-161,
1983.
39. Wilson G.B., Jonsson H.T., Halushka P.V.,
Garner B.P., Berkaw M.N. - Contribution of
prostaglandins to the biological activity of
Dyalizable Leukocytes Extracts containing
Transfer Factor. Ibidem, pp.137-150.
40. Wilson G.B., Metcalf J.F. jr., Fudenberg
H.H. - Treatment of Mycobacterium fortui-
tum pulmonary infection with Transfer Fac-
tor: New methodology for evaluating TF
potency and predicting clinical response.
Clin Immunol Immunopathol, 23, 478-
491, 1982.
41. Wilson G.B., Paddock G.V., Fudenberg
H.H.: Bovine “Transfer Factor”: an oligori-
bonucleopeptide wich initiates antigen-spe-
cific lymphocyte responsiveness. Thymus,
4: 335-350, 1982.
42. Wilson G.B., Paddock G.V., Fudenberg
H.H.: Effect of dialyzable leukocyte extracts
with transfer factor activity on leukocytes
migration in vitro. V. Antigen-specific
lymphocyte responsiveness can be iniated
by two structurally distinct polyribonucleoti-
des. Thymus 2: 257-276, 1981.
Literature references
Contact UsFor USA customersGUNA Incorporated1520 Tramway Blvd. NE, STE, 150 Albuquerque, New Mexico 87112, USA1-888-GUNA-TEL (486-2835)1-888-GUNA-FAX (486-2329)Contact your Medical Sales Consultant directly at: 505-217-3977 or fax to 505-217-3996Please give us your opinion and feedback by emailing us at info@gunainc.com
For all other countries outside the United StatesPlease email us at export@guna.it